CSPC Pharmaceutical Group Ltd.'s DP303c was granted the U.S. orphan drug designation to treat gastric cancer.
The designation from the U.S. Food and Drug Administration will help expedite development of the antibody-drug conjugate, which targets the human epidermal growth factor receptor 2, or HER2, protein in the body to fight cancer.
Approximately 15% to 20% of gastric cancer patients are HER2 positive.
The Chinese company said this new type of targeted drug can achieve better efficacy for the treatment of gastric cancer with fewer side effects and prolonged survival.
